OTC Prilosec In "MUPS" Formulation Confirmed By AstraZeneca Exec
This article was originally published in The Tan Sheet
Executive Summary
AstraZeneca's proton pump inhibitor Prilosec (omeprazole) will switch to OTC status in the U.S. in the "multi-unit pellet system" (MUPS) dosage form, Exec VP-Gastrointestinal Franchise Martin Nicklasson, PhD, stated at a briefing for securities analysts in London Dec. 6.
You may also be interested in...
Oral Contraceptives Have Strong Rx-To-OTC Consumer Support - Survey
Switching oral contraceptives for women from Rx-to-OTC status was viewed as a "good idea" by a majority of respondents to a recent survey conducted by the Guideline Research Group (New York).
Oral Contraceptives Have Strong Rx-To-OTC Consumer Support - Survey
Switching oral contraceptives for women from Rx-to-OTC status was viewed as a "good idea" by a majority of respondents to a recent survey conducted by the Guideline Research Group (New York).
Oral Contraceptives Have Strong Rx-To-OTC Consumer Support - Survey
Switching oral contraceptives for women from Rx-to-OTC status was viewed as a "good idea" by a majority of respondents to a recent survey conducted by the Guideline Research Group (New York).